SCHEMBL2285676

SCHEMBL2285676

CCCCCCCC/C=C\CCCCCCCC(O)=CCO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.58
PPARD Q03181 5/20 0.58
PPARA Q07869 5/20 0.58
F7 P08709 5/20 0.58
F3 P13726 5/20 0.58
TERT O14746 3/20 0.58
PTPN1 P18031 3/20 0.58
HSD17B10 Q99714 3/20 0.58
FABP4 P15090 3/20 0.58
MAPT P10636 2/20 0.58
BLM P54132 2/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2C19 P33261 2/20 0.58
FAAH O00519 2/20 0.58
KMT2A Q03164 2/20 0.58
LMNA P02545 2/20 0.58
ALOX15 P16050 2/20 0.58
DUSP3 P51452 2/20 0.58
CYP19A1 P11511 2/20 0.58
PTGS1 P23219 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL726983 0.89 PPARG (0.55) PPARGPPARDPPARAF7F3
SCHEMBL31373181 0.88 PPARG (0.62) PPARGPPARDPPARAF7F3
SCHEMBL9775730 0.84 PPARG (0.36) PPARGPPARDPPARAF7F3
SCHEMBL31373182 0.83 ALDH1A1 (0.66) PPARGPPARDPPARAF7F3
SCHEMBL5968107 0.82 PPARG (0.64) PPARGPPARDPPARAF7F3
SCHEMBL9439470 0.81 EP300 (0.54) PPARGPPARDPPARAF7F3
SCHEMBL17199787 0.81 EP300 (0.54) PPARGPPARDPPARAF7F3
SCHEMBL11857561 0.81 EP300 (0.54) PPARGPPARDPPARAF7F3
SCHEMBL15662569 0.81 EP300 (0.54) PPARGPPARDPPARAF7F3
SCHEMBL5974158 0.81 EP300 (0.54) PPARGPPARDPPARAF7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1331927-B1 TOPICAL COMPOSITION CONTAINING AT LEAST ONE VITAMIN D OR ONE VITAMIN D ANALOGUE AND AT LEAST ONE CORTICOSTEROID LEO PHARMA AS (DK) 2007-12-12 EP claimed
WO-2000044223-A9 USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE SYNGENTA LTD (GB) 2001-11-15 WO claimed
EP-1150563-A1 USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE Syngenta Limited (GB) 2001-11-07 EP claimed
EP-0746311-B1 MEDICINAL PATCHES FOR PERCUTANEOUS ADMINISTRATION PACIFIC CORP (KR) 2001-07-11 EP claimed
WO-2000044223-A1 USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE SYNGENTA LIMITED (GB) 2000-08-03 WO claimed
EP-0487958-B1 Transparent or semi-transparent cosmetic composition KAO CORP (JP) 1999-10-20 EP claimed
US-12139684-B2 Method for manufacturing coal additive KOREA JINTECH (KR) 2024-11-12 US disclosed
US-20240207411-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS SEAPORT THERAPEUTICS, INC. 2024-06-27 US disclosed
US-11975073-B2 Lipid prodrugs of neurosteroids PURETECH LYT, INC. (US) 2024-05-07 US disclosed
US-11938137-B2 Lipid prodrugs of mycophenolic acid and uses thereof PURETECH LYT, INC. (US) 2024-03-26 US disclosed
US-11883497-B2 Lymphatic system-directing lipid prodrugs PURETECH LYT, INC. (US) 2024-01-30 US disclosed
EP-4306524-A2 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS PureTech LYT, Inc. (US) 2024-01-17 EP disclosed
US-20230338552-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2023-10-26 US disclosed
US-4897214-A Skin cleaning preparations containing a HLB 10-19 non-ionic emulsifier and a thickening agent CRINOS INDUSTRIA FARMACOBIOLOGICA SPA. (IT) 1990-01-30 US disclosed
EP-0166337-B1 ELASTASE-CONTAINING HAIR CARE AGENT Eisai Co., Ltd. (JP) 1989-09-20 EP disclosed
US-4707293-A Detergent composition CRINOS INTERNATIONAL (CH) 1987-11-17 US disclosed
US-4604139-A Dual color ink composition SAKURA COLOR PRODUCTS CORP. (JP) 1986-08-05 US disclosed
EP-0166337-A1 Elastase-containing hair care agent Eisai Co., Ltd. (JP) 1986-01-02 EP disclosed
US-4545819-A Writing implement containing dual color ink composition Sakupa Color Products Corp. (JP) 1985-10-08 US disclosed
US-4490177-A Dual color ink composition SAKURA COLOR PRODUCTS CORP. (JP) 1984-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338552-A1 LIPID PRODRUGS OF NEUROSTEROIDS CYP21A2, CYP46A1, CYP17A1 PPARG 581/4885PPARD 1179/4885PPARA 807/4885
US-11938137-B2 Lipid prodrugs of mycophenolic acid and uses thereof MALT1, CYP2B6, LIPA PPARG 718/4885PPARD 1256/4885PPARA 621/4885
US-11883497-B2 Lymphatic system-directing lipid prodrugs LIPA, MALT1, SGMS1 PPARG 1409/4885PPARD 2083/4885PPARA 1346/4885
US-20240207411-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS LIPA, MALT1, SGMS1 PPARG 1409/4885PPARD 2083/4885PPARA 1346/4885
US-11975073-B2 Lipid prodrugs of neurosteroids CYP21A2, CYP46A1, CYP17A1 PPARG 581/4885PPARD 1179/4885PPARA 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.